Expertise in
2
conditions

Pio A. Lopez

Cali, VAC, CO 
Expertise in
2
conditions
Cali, VAC, CO 

Overview

Pio Lopez practices practicing medicine in Cali, Colombia.

Mr. Lopez is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Dengue Fever, Viral Hemorrhagic Fever, Pneumococcal Meningitis, Severe Acute Respiratory Syndrome (SARS), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 46 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Cali, VAC, Colombia
Other Locations
Colombia
Valle De San Jose, SAN, Colombia
El Bosque, SAN, Colombia
Pereira, RIS, Colombia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 2b, Double-blind, Randomized, Multi-site, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of Intramuscular HIL-214 Norovirus Vaccine in Healthy Children 5 Months of Age at Initial Vaccination
A Phase 2b, Double-blind, Randomized, Multi-site, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of Intramuscular HIL-214 Norovirus Vaccine in Healthy Children 5 Months of Age at Initial Vaccination
Enrollment Status: Terminated
Publish Date: July 10, 2025
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multi-center, Observer-blind, Randomized, Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019), Administered as a Booster Dose to Adults, Who Previously Received Primary Series of a COVID-19 Vaccine
A Multi-center, Observer-blind, Randomized, Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019), Administered as a Booster Dose to Adults, Who Previously Received Primary Series of a COVID-19 Vaccine
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Biological
Study Phase: Phase 3
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Randomized, Controlled, Dose-finding, Observer-blind, Phase 2/3 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccines (SCB-2019 Vaccine) in Children <18 Years of Age
A Randomized, Controlled, Dose-finding, Observer-blind, Phase 2/3 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccines (SCB-2019 Vaccine) in Children <18 Years of Age
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

46 Total Publications

From Venezuela to Colombia: Translating Lessons on Infectious Diseases and Vaccination into Risk-Based Preparedness after the 2026 Earthquakes.
From Venezuela to Colombia: Translating Lessons on Infectious Diseases and Vaccination into Risk-Based Preparedness after the 2026 Earthquakes.
Journal: Travel medicine and infectious disease
Published: September 01, 2026

Frequently Asked Questions about Pio A. Lopez

Is Pio A. Lopez a top-rated expert for Dengue Fever?

MediFind is an objective health platform that identifies experts based on real-world data. Pio A. Lopez is classified as an Advanced expert for Dengue Fever, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Pio A. Lopez participate in research or clinical trials?

Yes. Pio A. Lopez has published 46 articles and abstracts on conditions like Dengue Fever. You can view a list of Pio A. Lopez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lopez's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile